Amundi and Sand Grove Capital Launch Event Driven UCITS Fund (Opalesque.com)
Opalesque Industry Update – Amundi, the largest European asset manager, and Sand Grove Capital Management LLP, announce the launch of the Amundi Sand Grove Event Driven Fund. Available on the Amundi Alternatives UCITS platform, the Fund employs a global event-driven equity strategy with a European tilt and seeks to capitalise on mispricings in corporate events such as takeovers, mergers, exchange offers, restructurings and liquidations. The Fund draws on Sand Grove’s founder and CIO Simon Davies’ 22 years of expertise in event-driven investing, cultivated over multiple market cycles as well as Amundi’s market-leading UCITS managed account platform.
China Hedge Fund Makes Rare Activist Push Targeting US, HK Firms (Bloomberg)
A Chinese hedge fund manager is launching a rare activist campaign to boost returns. Huakun Ding, founder of Goldenwise Capital Group, set his sights on New York-listed GEE Group Inc., buying a stake of more than 5% and pushing for changes including a potential sale of the human resources firm. GEE shares have jumped 28% since Goldenwise’s Aug. 15 filing.
Nordkinn Gears Up for Next Decade with Key Appointment (Hedge Nordic)
Stockholm (HedgeNordic) – Shortly after celebrating its tenth anniversary this summer, Nordkinn Fixed Income Macro Fund welcomed Anders Augusén as an investment manager effective September 1. Augusén, renowned for his long and successful career as a portfolio manager at Brummer & Partners-backed Nektar Asset Management, also co-founded and co-managed Frost Asset Management’s now-closed fixed-income relative value fund. Before joining Nordkinn, he briefly worked at Barclays Corporate and Investment Bank.
Monday 9/18 Insider Buying Report: IOVA, CHPT (Nasdaq.com)
At Iovance Biotherapeutics, a filing with the SEC revealed that on Friday, Director Wayne P. Rothbaum purchased 5,000,000 shares of IOVA, at a cost of $5.30 each, for a total investment of $26.5M. So far Rothbaum is in the green, up about 14.2% on their purchase based on today’s trading high of $6.05. Iovance Biotherapeutics is trading up about 13.1% on the day Monday. Before this latest buy, Rothbaum made one other buy in the past year, purchasing $65M shares at a cost of $6.50 a piece. And at ChargePoint Holdings, there was insider buying on Wednesday, by Bruce R. Chizen who bought 500,000 shares at a cost of $5.79 each, for a trade totaling $2.9M. This purchase marks the first one filed by Chizen in the past twelve months.
Over $6M Bet On ModivCare? Check Out These 3 Stocks Insiders Are Buying (Benzinga)
ModivCare: The Trade: ModivCare Inc. (MODV) Director Adam Gray acquired a total of 213,248 shares an average price of $29.82. To acquire these shares, it cost around $6.36 million. Semler Scientific: The Trade: Semler Scientific, Inc. (SMLR) Director Eric Semler acquired a total of 77,771 shares at an average price of $27.61. To acquire these shares, it cost around $2.15 million.
